Skip to search formSkip to main contentSkip to account menu

lobeglitazone

An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Besides its activation of peroxisome proliferator… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

CKD 501

Broader (2)

PyrimidinesThiazolidinediones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pinned orbital moments in uncompensated antiferromagnetic Co doped ZnO
Low temperature Co K-edge x-ray magnetic circular dichroism spectra at different field cooling conditions were recorded to study… 
2018
2018
Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance. The peroxisome proliferator-activated… 
2017
2017
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Background Renal tubulointerstitial fibrosis is a common feature of the final stage of nearly all cause types of chronic kidney… 
2017
2017
Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
Background Bone strength is impaired in patients with type 2 diabetes mellitus despite an increase in bone mineral density (BMD… 
2017
2017
Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes.
2017
2017
Design, sythesis and evaluation of a series of 3- or 4-alkoxy substituted phenoxy derivatives as PPARs agonists
Peroxisome proliferators-activated receptors (PPARα, γ and δ) are potentially effective targets for Type 2 diabetes mellitus… 
2017
2017
Supplementary material : Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes
Diabetes & Metabolism - In Press.Proof corrected by the author Available online since vendredi 15 decembre 2017 
2017
2017
Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
Peroxisome proliferator-activator receptor (PPAR) γ is a nuclear hormone receptor that regulates glucose homeostasis, lipid… 
2015
2015
Gender differences in the hepatic elimination and pharmacokinetics of lobeglitazone in rats.
The pharmacokinetics of lobeglitazone (LB) was studied after intravenous administration at a dose of 1 mg/kg and oral… 
2015
2015
Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)